Communiqués Kodiak Sciences Inc.

Actions

KOD

US50015M1099

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 07/10/2026			Varia. 5j.	Varia. 1 janv.
91,08 ^USD	-1,36%		-0,04%	+225,75%

18:51	Kodiak Sciences Inc. présente des données cliniques sur ses trois programmes en phase avancée lors de l’AAO 2026	CI
06/10	Kodiak Sciences, valeur de la semaine de Smart Insider après l’achat d’actions par un initié	MT

Communiqués

13:01	Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026	PR
28/09	Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.	PR
26/09	Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration	PR
13/08	Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results	PR
10/08	Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema	PR
06/08	Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026	PR
29/05	Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference	PR
08/05	Kodiak Sciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results	PR
04/05	Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences	AQ
01/05	Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences	PR
31/03	Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results	PR
26/03	Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham	PR
06/02	Kodiak Sciences : APEX Week 24 Results Angiogenesis VF (Website)	PU
04/02	Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026	PR
12/01	Kodiak Sciences : JPM vFinal	PU
08/01	Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference	PR
19/12	Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares	PR
17/12	Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock	PR
15/12	Kodiak Sciences Announces Proposed Public Offering of Common Stock	PR
17/11	Kodiak Sciences : Jefferies Global Healthcare Conference London November 2025	PU
13/11	Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results	PR
12/11	Kodiak Sciences to Present at Upcoming Investor Conferences	PR
05/11	Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)	PR
15/09/25	New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)	PR